Successful Treatment of Osteonecrosis-induced Fractured Mandible with Teriparatide Therapy: A Case Report

Overview

Journal Int J Surg Case Rep

Specialty General Surgery

Date 2016 Mar 8

PMID 26947555

Citations 3

Authors

Mayumi Yao

Tsuyoshi Shimo

Yuko Ono

Kyoichi Obata

Norie Yoshioka

Akira Sasaki

Affiliations

Soon will be listed here.

Abstract

Introduction: The management of medication-related osteonecrosis of the jaw (MRONJ) is controversial. To date, there is no established treatment for cases of advanced stage 3 MRONJ osteoporosis in elderly patients.

Presentation: An 87-year-old osteoporotic woman with osteonecrosis-induced left mandible fracture related to minodronate therapy was referred to us for treatment. She had a vertebral compression fracture concurrently and had started subcutaneous injection of teriparatide. After 18 months of treatment with teriparatide the pathological mandible fracture was healed and functional recovery of the occlusion was obtained by complete dentures.

Discussion: Teriparatide may have a powerful anabolic effect on bone, and promote bone regeneration against pathologic mandible fracture induced by MRONJ.

Conclusion: Based upon these findings, teriparatide might be beneficial for advanced stage 3 MRONJ osteoporosis in elderly patients.

Citing Articles

A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture.

Fernandes T, Fernandes B, Jitumori C, Franco G Am J Case Rep. 2023; 24:e941144.

PMID: 37867315 PMC: 10614430. DOI: 10.12659/AJCR.941144.

Effect of diode laser biostimulation compared to Teriparatide on induced osteoporosis in rats: an animal study from Egypt.

Hamza S, Fathy S, El-Azab S Int J Clin Exp Pathol. 2020; 13(8):1970-1985.

PMID: 32922592 PMC: 7476941.

Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw.

Zandi M, Dehghan A, Amini P, Doulati S, Rezaeian L Clin Oral Investig. 2019; 23(11):3987-3993.

PMID: 30715621 DOI: 10.1007/s00784-019-02830-2.

References

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S . Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015; 44(5):568-85. DOI: 10.1016/j.ijom.2015.01.026. View

Miyakoshi N, Horikawa A, Shimada Y . Nonsurgical Corrective Union of Osteoporotic Vertebral Fracture with Once-Weekly Teriparatide. Case Rep Orthop. 2015; 2015:784360. PMC: 4534610. DOI: 10.1155/2015/784360. View

Silva L, Curra C, Munerato M, Deantoni C, Matsumoto M, Cardoso C . Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. Oral Maxillofac Surg. 2015; 20(1):9-17. DOI: 10.1007/s10006-015-0538-x. View

Kim K, Park W, Oh S, Kim H, Nam W, Lim S . Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int. 2014; 25(5):1625-32. DOI: 10.1007/s00198-014-2622-8. View

Charles J, Aliprantis A . Osteoclasts: more than 'bone eaters'. Trends Mol Med. 2014; 20(8):449-59. PMC: 4119859. DOI: 10.1016/j.molmed.2014.06.001. View

Harper R, Fung E . Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007; 65(3):573-80. DOI: 10.1016/j.joms.2006.10.076. View

Carlson E, Basile J . The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):85-95. DOI: 10.1016/j.joms.2009.01.006. View

Lee J, Cheng S, Jeng J, Chiang C, Lau H, Kok S . Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck. 2010; 33(9):1366-71. DOI: 10.1002/hed.21380. View

10.

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

11.

Yamachika E, Matsubara M, Ikeda A, Matsumura T, Moritani N, Iida S . Treatment of Osteonecrosis of the Jaw. J Craniofac Surg. 2015; 26(7):e575-7. DOI: 10.1097/SCS.0000000000002127. View

12.

Lim S, Bolster M . Current approaches to osteoporosis treatment. Curr Opin Rheumatol. 2015; 27(3):216-24. DOI: 10.1097/BOR.0000000000000169. View

13.

Rao M, Berk J, Almojaly S, Goodloe Iii S, Margarone Iii J, Sullivan M . Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy. Int J Mol Med. 2009; 23(3):407-13. DOI: 10.3892/ijmm_00000145. View

14.

Jiang Y, Zhao J, Mitlak B, Wang O, Genant H, Eriksen E . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18(11):1932-41. DOI: 10.1359/jbmr.2003.18.11.1932. View

15.

Gomberg S, Wustrack R, Napoli N, Arnaud C, Black D . Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011; 96(6):1627-32. DOI: 10.1210/jc.2010-2520. View